The monitoring schemes were developed in the presence of the right censoring at fixed level.
The performances of monitoring schemes were investigated by the ARL values.
Factors to be considered in the design of future monitoring schemes are also discussed.
It is remarkable that the proposed monitoring schemes are extended when the censoring occurred in these stages.
In this sub-section, monitoring schemes are developed in the absence of both the fixed- and variable-competing risks.
Comprehensive and standardized biodiversity monitoring schemes are needed to build scientifically sound decision-making tools for biodiversity conservation.
In recent years, several distribution-free process monitoring schemes are introduced in the literature to monitor both the location and scale parameters simultaneously.
Thus, spatially differentiated monitoring schemes are needed, in particular with regard to biodiversity (e.g. non-target organisms) and ecological processes and functions (e.g. soil functions) in which these organisms are involved.
Standardized drug level monitoring schemes are in general highly recommended.
Finally, it is important that patient monitoring schemes be enhanced and standardized since it will allow for improved measurement of patient responses and direct comparison of different clinical trials.
